Riken Vitamin Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects net sales to be JPY 88,000 million against previous guidance of JPY 86,000 million. Operating income to be JPY 6,800 million against previous guidance of JPY 5,700 million.

Net income attributable to owners of parent to be JPY 5,600 million against previous guidance of JPY 4,700 million. Earnings per share to be JPY 170.70 against previous guidance of JPY 143.27. Reasons for the Consolidated Forecast Revision: In the domestic business, price revisions have been unable to keep pace with increases in raw material and energy prices.

In the overseas business, both net sales and operating income are expected to grow substantially due to the effects of price revisions and the impact of foreign exchange rates. The Company has therefore revised its full-year forecasts for net sales and each income category.